Related Experiment Video
Updated: Aug 12, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
THE INCREASED PLASMA LEVELS OF INTERMEDIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
1Civil Aviation General Hospital, Department of Endocrinology, Beijing, China.
Acta Endocrinologica (Bucharest, Romania : 2005)
|January 26, 2023
Summary
Plasma levels of intermedin (IMD) were elevated in patients with type 2 diabetes mellitus (T2DM). However, IMD showed limited diagnostic value for T2DM, indicating it may not be suitable for disease diagnosis.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Biomarker Discovery
Background:
- Intermedin (IMD), a member of the calcitonin gene-related peptide family, is associated with type 2 diabetes mellitus (T2DM).
- The alteration of plasma IMD levels in T2DM patients remains unclear.
Purpose of the Study:
- To investigate plasma intermedin (IMD) levels in patients diagnosed with type 2 diabetes mellitus (T2DM).
Main Methods:
- Plasma IMD levels were quantified using ELISA in 41 T2DM patients and 44 healthy controls.
- The diagnostic utility of IMD was assessed via receiver operating characteristic (ROC) curve analysis.
Main Results:
- Plasma IMD levels were significantly higher in the T2DM group compared to the control group.
- IMD levels correlated with BMI, DBP, triglycerides, uric acid, urea nitrogen, blood glucose (fasting and postprandial), and HbA1c.
- The area under the ROC curve (AUC) for IMD was 58.73%, indicating low diagnostic value.
Conclusions:
- Plasma IMD levels are increased in individuals with T2DM.
- The diagnostic performance of IMD for T2DM is insufficient for clinical application in disease diagnosis.
More Related Videos
08:03Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
20.1K
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
68.9K
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
226
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
226
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
253
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
253
01:22Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
01:24Glucagon-like Receptor Agonists
382
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
382
01:06Oral Hypoglycemic Agents: Glinides
204
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
204
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
232
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
232